LD-2 disclosure · 4th Quarter - Report
BIOGEN, INC.
via DLA PIPER LLP (US)
Client
- Name
- BIOGEN, INC.
- Description
- Biotechnology company.
- Location
- District of Columbia · United States of America
Registrant
- Firm
- DLA PIPER LLP (US)
- Description
- Law firm.
- Location
- Washington, District of Columbia, United States of America
Lobbying activities
6 issuesHealth Issues
Issues related to rare diseases including Alzheimer's disease, Amyotrophic lateral sclerosis (ALS), Lou Gehrig's Disease. Drug pricing and drug development policies. Screening and diagnosis. Patient affordability and access issues, including copay cards, copay accumulators, copay maximizers, coverage issues. Orphan Drug Act. Issues related to the FDA including PDUFA, drug reviews, approval pathways, and clinical trials. Policies related to value based arrangements.
LobbyistsMARGARET MARTIN · MICHAEL SORENSEN · RACHEL PORTMAN · KARINA LYNCH · RICHARD BURR · MAREN MCBRIDE
Covered position (RACHEL PORTMAN): Deputy Health Policy Director, Committee on Senate Health, Education, Labor and Pensions; Health Policy Assistant, Sen. Richard Burr; Intern, Sen. Robert Portman
Covered position (MAREN MCBRIDE): Counsel, Rep. Mollohan
TargetedSENATE · HOUSE OF REPRESENTATIVES · Health & Human Services, Dept of (HHS) · Centers For Medicare and Medicaid Services (CMS)
Medical/Disease Research/Clinical Labs
Issues related to rare disease and treatment. Drug pricing policy. Issues related to the Medicaid 340B program. Public policy around patients' access and affordability. Alzheimer's disease. Issues related to Medicare Part B and D.
LobbyistsMARGARET MARTIN · MICHAEL SORENSEN · RACHEL PORTMAN · KARINA LYNCH · RICHARD BURR · MAREN MCBRIDE
Covered position (RACHEL PORTMAN): Deputy Health Policy Director, Committee on Senate Health, Education, Labor and Pensions; Health Policy Assistant, Sen. Richard Burr; Intern, Sen. Robert Portman